Clinical Scorecard: Tenecteplase Fails to Boost EVT Outcomes

At a Glance

Key Highlights

• No significant improvement in functional independence at 90 days with tenecteplase prior to EVT compared to EVT alone.
• Functional independence occurred in 44% of tenecteplase patients vs. 43% in EVT alone.
• Median time from symptom onset to randomization was approximately 10 hours.
• Symptomatic intracranial hemorrhage occurred in 5% of tenecteplase patients vs. 3% in EVT alone.

Guideline-Based Recommendations

Diagnosis

Management

• Consider endovascular treatment alone for patients presenting within 4.5 to 24 hours.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

391 adults enrolled in the TNK-PLUS trial across 40 centers in China.

Median time from hospital admission to tenecteplase administration was 90 minutes.

Clinical Best Practices

• Assess salvageable brain tissue using imaging criteria before considering thrombolysis.
• Evaluate the timing of treatment administration in relation to endovascular procedures.

Related Resources & Content

• JAMA TNK-PLUS Trial